Relaxin gene therapy: A promising new treatment option for various diseases with aberrant fibrosis or irregular angiogenesis
- Title
- Relaxin gene therapy: A promising new treatment option for various diseases with aberrant fibrosis or irregular angiogenesis
- Author
- 윤채옥
- Keywords
- Relaxin; Gene therapy; Cardiac dysfunction; Cancer; Liver cirrhosis
- Issue Date
- 2019-05
- Publisher
- ELSEVIER IRELAND LTD
- Citation
- MOLECULAR AND CELLULAR ENDOCRINOLOGY, v. 487, Page. 80-84
- Abstract
- Relaxin (RLX) is an insulin-like polypeptide hormone that was initially introduced for its pregnancy-related function. Subsequent studies revealed that RLX possesses anti-fibrotic functions in tumors and nonreproductive tissues, such as skin, lungs, and others. This aspect of the RLX has been explored for the treatment of various illnesses, such as cardiac fibrosis, liver fibrosis, and solid tumors. With gene therapy coming into age with increasing number of products being approved by regulatory bodies in Europe and United States, we aim to discuss how RLX have been utilized in scope of gene therapy for treatment of various illnesses.
- URI
- https://www.sciencedirect.com/science/article/pii/S0303720719300097?via%3Dihubhttps://repository.hanyang.ac.kr/handle/20.500.11754/111893
- ISSN
- 0303-7207
- DOI
- 10.1016/j.mce.2019.01.009
- Appears in Collections:
- COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML